SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Elon Musks warning that neocloud providers face tighter debt access and industry consolidation has fueled concern about Nebius and its peers. Traders debate whether Nebius is exposed to those risks, with bulls pointing to its recent financing and managements statement that it has enough funding for planned expansion.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is drawing attention amid a sharp selloff in AI neocloud stocks, fueled by Elon Musks warning of industry failures and consolidation alongside broader concerns about debt and data-center financing. Traders are divided between fears that capital constraints could threaten the business and claims that the selling is sector-wide FUD, with bulls pointing to IRENs contracts and infrastructure as reasons to buy the dip.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas Phase 3 personalized melanoma-vaccine results with Mercks Keytruda dominate discussion: traders generally describe the clinical data as positive, but say it fell short of lofty expectations after a steep rally, prompting a sharp selloff. The debate centers on whether the vaccines benefits can translate into broader cancer applications and commercial returns, or whether valuation, manufacturing and adoption risks limit the opportunity.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nus strong quarterly results, including record profitability and continued growth, have fueled a share-price rebound. Traders are split between viewing the results as evidence of a strong business and expecting profit-taking, with some frustrated that solid fundamentals have not led to sustained gains.

Petróleo Brasileiro SA engages in oil and gas exploration, production, and distribution activities. It operates through the following segments: Exploration and Production; Refining, Transportation, and Marketing; and Gas and Low Carbon Energies. The Exploration and Production segment covers the activities of exploration, development, and production of crude oil, natural gas liquid, and natural gas, for the primary purpose of supplying its domestic refineries. The Refining, Transportation, and Marketing segment refers to refining, logistics, transport, and trading of crude oil and oil products activities as well as exports of ethanol. The Gas and Low Carbon Energies represents the activities of logistic and trading of natural gas and electricity, transportation and trading of liquefied natural gas, generation and electricity by means of thermoelectric power plants, as well as holding interests in transporters and distributors of natural gas. The company was founded on October 3, 1953 and is headquartered in Rio de Janeiro, Brazil.

Petroleo Brasileiro S.A. Petrobras - ADR

Petroleo Brasileiro

Lulas election victory over Bolsonaro has prompted a sharp repricing of Brazilian stocks, with traders concerned about political uncertainty and Petrobrass state ownership and dividend outlook. The community is split between sellers who see further risk and investors treating the selloff as a buying opportunity, citing the companys oil business and dividends.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Discussion centers on SELLASs Phase 3 REGAL trial of its GPS cancer vaccine for AML, with traders citing the last reported count of 78 of 80 events and awaiting the final analysis and topline results. Bulls interpret the prolonged wait as a possible sign of extended survival, while skeptics question the delay and the companys silence; SLS009 milestones and a possible ASH presentation are secondary topics.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

Lulas unexpected election victory over Bolsonaro has driven a sharp selloff in Brazilian assets, with traders citing uncertainty over economic policy and the markets prior preference for Bolsonaro. Some see the decline as a buying opportunity, while others expect further weakness.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Attention centers on AbCelleras ABCL635 clinical update for menopausal hot flashes, with traders focused on the Phase 1/2 safety and patient-reported data and looking for evidence that the encouraging Phase 2 results hold up over time. Bulls see the update and analyst coverage as support for the pipeline story, while skeptics argue the presentation may add little beyond known results and note the stocks volatility.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visa is drawing attention ahead of its fiscal fourth-quarter and full-year report, with traders focused on the outlookparticularly marginsand how the stock reacts after the release. Bulls point to its strength near record highs, while skeptics say expectations may be priced in and warn that soft guidance could prompt a pullback.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens IMDELLTRA-and-IMFINZI combination showed a substantial survival benefit in a Phase 3 trial for extensive-stage small-cell lung cancer, prompting traders to discuss the drugs potential as a growth driver. The reaction is broadly optimistic, with some attention also on Repathas sales growth and the stocks recent run.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$DBI Outstanding article that hits the mark on DBI&#39;s current state. So if you want to refresh your DBI insights or learn about DBI from scratch, this is a must read. https://everyticker.com/quote/DBI/analysis/margin-inflection-meets-brand-portfolio-acceleration-at-designer-brands-nyse-dbi

David Levy

Designer Brands is executing a turnaround where its Brand Portfolio segment (+19.4% Q1 sales, +693% operating profit) is driving margin expansion while the core Retail segment stabilizes. The stock tr...

EveryTicker

Margin Inflection Meets Brand Portfolio Acceleration at Designer Brands (NYSE:DBI) - DBI Research Report

StockTwits Web

Designer Brands Inc - Ordinary Shares - Class A

 Outstanding article that hits the mark on DBI's current state. So if you want to refresh your DBI insights or learn about DBI from scratch, this is a must read. 